Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1

Neuromuscular Disorders

Volumn 25, Issue 4, 2015, Pages 308-320

  Algalarrondo, Vincent ^a,b   Wahbi, Karim ^c,d   Sebag, Frédéric ^a   Gourdon, Geneviève ^e,f   Beldjord, Chérif ^c,g   Azibi, Kamel ^c   Balse, Elise ^a   Coulombe, Alain ^a   Fischmeister, Rodolphe ^b   Eymard, Bruno ^d   Duboc, Denis ^c,d   Hatem, Stéphane N ^a  

^a Sorbonne Universités   (France)

^b Universite Paris Sud   (France)

^c Institut Cochin   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL BROUSSAIS   (France)

^f IMAGINE INSTITUTE   (France)

^g CNRS   (France)

Author keywords

Arrhythmia basic study; Conduction disorders; Electrophysiology; Myotonic dystrophy type 1; Sodium current channelopathy; Steinert disease; Transgenic mice

Indexed keywords

FLECAINIDE; SODIUM CHANNEL NAV1.5; ANTIARRHYTHMIC AGENT; SCN5A PROTEIN, MOUSE; SODIUM; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC SODIUM CURRENT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART VENTRICLE FUNCTION; MALE; MICROELECTRODE; MOUSE; MOUSE MODEL; MYOTONIC DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCN5A GENE; SODIUM CURRENT; TRANSGENIC MOUSE; WHOLE CELL PATCH CLAMP; WILD TYPE; ACTION POTENTIAL; AGING; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; CONGENITAL MALFORMATION; DISEASE MODEL; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; GENETICS; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; AGING; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, DOPPLER; FLECAINIDE; HEART CONDUCTION SYSTEM; MALE; MICE, TRANSGENIC; MICROELECTRODES; MODELS, CARDIOVASCULAR; MODELS, NEUROLOGICAL; MYOCYTES, CARDIAC; MYOTONIC DYSTROPHY; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PATCH-CLAMP TECHNIQUES; SODIUM; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84925248589     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.11.018     Document Type: Article

References (45)

1. Ashizawa T., Epstein H.F. Ethnic distribution of myotonic dystrophy gene. Lancet 1991, 338:642-643.
2. Mahadevan M., Tsilfidis C., Sabourin L., et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255:1253-1255.
3. Amack J.D., Paguio A.P., Mahadevan M.S. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet 1999, 8:1975-1984.
4. Mankodi A., Logigian E., Callahan L., et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000, 289:1769-1773.
5. De Die-Smulders C.E., Howeler C.J., Thijs C., et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998, 121(Pt 8):1557-1563.
6. Mathieu J., Allard P., Potvin L., Prevost C., Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999, 52:1658-1662.
7. Wahbi K., Meune C., Porcher R., et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012, 307:1292-1301.
8. Wang G.S., Kearney D.L., De Biasi M., Taffet G., Cooper T.A. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 2007, 117:2802-2811.
9. Gladman J.T., Mandal M., Srinivasan V., Mahadevan M.S. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1). PLoS ONE 2013, 8:e72907.
10. Mahadevan M.S., Yadava R.S., Yu Q., et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006, 38:1066-1070.
11. Wahbi K., Algalarrondo V., Bécane H.M., et al. Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. Arch Cardiovasc Dis 2013, 106:635-643.
12. Pambrun T., Mercier A., Chatelier A., et al. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation. Heart Rhythm 2014, 11:1393-1400.
13. Huguet A., Medja F., Nicole A., et al. Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genet 2012, 8:e1003043.
14. Panaite P.-A., Kuntzer T., Gourdon G., Lobrinus J.A., Barakat-Walter I. Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy. Dis Model Mech 2013, 6:622-631.
15. Panaite P.-A., Kielar M., Kraftsik R., Gourdon G., Kuntzer T., Barakat-Walter I. Peripheral neuropathy is linked to a severe form of myotonic dystrophy in transgenic mice. J Neuropathol Exp Neurol 2011, 70:678-685.
16. Seznec H., Lia-Baldini A.S., Duros C., et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet 2000, 9:1185-1194.
17. Gomes-Pereira M., Foiry L., Nicole A., et al. CTG trinucleotide repeat "big jumps": large expansions, small mice. PLoS Genet 2007, 3:e52.
18. Enclund A., Bergfeldt L., Rosenqvist M. Pharmacological stress testing of the His-Purkinje system in patients with bifascicular block. Pacing Clin Electrophysiol 1998, 21:1979-1987.
19. Martin C.A., Zhang Y., Grace A.A., Huang C.L. In vivo studies of Scn5a+/- mice modeling Brugada syndrome demonstrate both conduction and repolarization abnormalities. J Electrocardiol 2010, 43:433-439.
20. Remme C.A., Verkerk A.O., Nuyens D., et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006, 114:2584-2594.
21. Sebag I.A., Handschumacher M.D., Ichinose F., et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005, 111:2611-2616.
22. 2+ current and protects against ventricular arrhythmias in mice. J Clin Invest 2011, 121:2651-2661.
23. Mohler P.J., Rivolta I., Napolitano C., et al. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci U S A 2004, 101:17533-17538.
24. DiFrancesco D., Noble D. A model of cardiac electrical activity incorporating ionic pumps and concentration changes. Philos Trans R Soc Lond B Biol Sci 1985, 307:353-398.
25. Groh W.J., Groh M.R., Saha C., et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008, 358:2688-2697.
26. Walzik S., Schroeter A., Benndorf K., Zimmer T. Alternative splicing of the cardiac sodium channel creates multiple variants of mutant T1620K channels. PLoS ONE 2011, 6:e19188.
27. Hermans M.C.E., Faber C.G., Bekkers S.C.A.M., et al. Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2012, 14:48.
28. Lazarus A., Varin J., Babuty D., Anselme F., Coste J., Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol 2002, 40:1645-1652.
29. Nazarian S., Wagner K.R., Caffo B.S., Tomaselli G.F. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol 2011, 34:171-176.
30. Follmer C.H., Colatsky T.J. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990, 82:289-293.
31. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 2002, 136:717-729.
32. Ramos E., O'leary M.E. State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol 2004, 560:37-49.
33. Wolpert C., Echternach C., Veltmann C., et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005, 2:254-260.
34. Chiale P.A., Przybylski J., Laiño R.A., et al. Usefulness of the ajmaline test in patients with latent bundle branch block. Am J Cardiol 1982, 49:21-26.
35. Dubner S., Azocar D., Gallino S., et al. Single oral flecainide dose to unmask type 1 Brugada syndrome electrocardiographic pattern. Ann Noninvasive Electrocardiol 2013, 18:256-261.
36. Meregalli P.G., Ruijter J.M., Hofman N., Bezzina C.R., Wilde A.A.M., Tan H.L. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17:857-864.
37. Lindqvist P., Mörner S., Olofsson B.O., et al. Ventricular dysfunction in type 1 myotonic dystrophy: electrical, mechanical, or both?. Int J Cardiol 2010, 143:378-384.
38. Haugaa K.H., Edvardsen T., Leren T.P., Gran J.M., Smiseth O.A., Amlie J.P. Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome. Eur Heart J 2009, 30:330-337.
39. Tan H.L., Bink-Boelkens M.T., Bezzina C.R., et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001, 409:1043-1047.
40. Hondeghem L.M., Katzung B.G. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977, 472:373-398.
41. Dumaine R., Towbin J.A., Brugada P., et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999, 85:803-809.
42. Maury P., Audoubert M., Cintas P., et al. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: myotonic dystrophy as a part of the Brugada syndrome. Heart Rhythm 2014, 11:1721-1727.
43. Charlet B.N., Savkur R.S., Singh G., Philips A.V., Grice E.A., Cooper T.A. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002, 10:45-53.
44. Buj-Bello A., Furling D., Tronchère H., et al. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet 2002, 11:2297-2307.
45. + channel transcript patterns in the mammalian heart are species-dependent. Prog Biophys Mol Biol 2008, 98:309-318.